Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
A long-term follow-up study was carried out in 44 Type II diabetic patients to confirm the lack of effect of gliclazide on body weight as well as its hypoglycaemic efficacy and tolerance. Patients were assessed for up to 51 months. The results showed no overall significant change in body weight, 21 patients gaining weight (mean 3.59 +/- 2.6 kg), 20 patients losing weight (mean 3.39 +/- 2.6 kg) and 3 patients showing no weight change. Satisfactory hypoglycaemic control was achieved in all but 8 patients who were transferred to insulin. Clinical and biochemical tolerance was good.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000009:adverse effects*; D013997:Time Factors
D001786:Blood Glucose; D013453:Sulfonylurea Compounds; D005907:Gliclazide